Blog

  • Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025

    • Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation.
    • Oral presentation highlights the association between HDF and reduced risk of cardiovascular and fluid-related hospitalization outcomes.
    • Research shows how artificial intelligence is moving from theory into practice, supporting clinicians and patients in daily kidney disease care.


    Bad Homburg (October 30, 2025)
    – Fresenius Medical Care AG (FME), the world’s leading provider of products and services for people with kidney diseases, will present new research showing how hemodiafiltration (HDF) is associated with improved outcomes for kidney patients and how innovations in artificial intelligence (AI) can support clinicians in daily care at the American Society of Nephrology (ASN) Kidney Week 2025, November 5-9 in Houston.

    “This research reflects Fresenius Medical Care’s commitment to patient-centered innovation, demonstrating how advanced therapies like hemodiafiltration can be tailored to improve outcomes in real-world settings,” said Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care. “By applying novel physical principles to kidney replacement therapy, we are leading the field in delivering transformative solutions that elevate the standard of care and advance precision medicine globally.”

    FME’s Global Medical Office will present multiple abstracts across a range of critical topics in nephrology, underscoring the company’s commitment to advancing kidney care through innovation and evidence-based science.

    Key presentations include: 

    • Hemodiafiltration is associated with reduced risk of cardiovascular and fluid-related hospitalization outcomes: Highlights how HDF may lower the risk of cardiovascular- and fluid-related hospitalizations.
    • Implementation of Online High-Volume Hemodiafiltration in a Chronic Hemodialysis Center in the U.S.: Describes the first chronic dialysis unit to introduce high-volume HDF in the U.S.
    • Preventing Falls in Patients on Dialysis Through Artificial Intelligence (AI)-Driven Risk Prediction: Showcases an AI model that predicts patients’ fall risk within a 31-day period.
    • Supporting Clinician Adoption of Hemodiafiltration: A Real-Time Artificial Intelligence (AI) Chatbot with Verified Clinical Sources: Introduces a clinician-facing AI chatbot  designed to educate and support clinicians implementing HDF.
    • From Prompt to Plate: Can ChatGPT Plan a Safe and Clinically Appropriate Diet for Hemodialysis Patients?: Evaluates whether generative AI and large language models can provide safe, nutritionally accurate meal plans for dialysis patients.

    “It excites us to see how our research and innovation can translate to everyday practice,” said Maddux. “By combining real-world evidence with innovative technologies, Fresenius Medical Care is helping shape the future of nephrology and set new standards for kidney care.”

    In addition to scientific presentations, FME will participate in the following events during ASN Kidney Week:

    • FME will host a breakfast symposium, “HighVolumeHDF: The Next Standard of Care for U.S. Patients – Evidence and Practical Use,” as part of the ASN Exhibitor Spotlight series (Thursday, November 6).
    • ASN will present an educational symposium, “Hemodiafiltration: Considerations for Incorporation into Dialysis Care,” supported by an educational grant from Fresenius Medical Care (Friday, November 7).
    • The Renal Research Institute (RRI), a subsidiary of Fresenius Medical Care, will host its annual symposium, “Reimagining Frontline Care: The Power of Research, AI, and Innovation,” highlighting real-world applications of AI and digital tools in kidney care (Tuesday, November 4).

    FME leaders and researchers will also be available onsite at Booth #1815 to discuss research insights, clinical collaborations, and innovations in kidney care. Representatives from RRI will be available at Booth #1838.

    To learn more about the company’s presence at ASN this year, please visit https://freseniusmedicalcare.com/en-us/asn-2025/.

     

    Continue Reading

  • BBVA CIB reports record revenues of €4,832 million through September

    BBVA CIB reports record revenues of €4,832 million through September

    Sustained growth in client activity, driven by sector specialization

    Despite global uncertainty, BBVA CIB has reinforced its commitment to supporting the sustained growth of wholesale clients in 2025, thanks to a sector specialization model built on tailored solutions and a long-term strategic vision.

    This approach is reflected in a 16% year-on-year increase in revenues from the corporate segment through September, with particularly strong performance in the energy (+23%), consumer & retail (+19%) and TMT (+16%) sectors. In the institutional segment, growth accelerated to 23% year-on-year, driven by strong performance in the public sector (60%) and among financial sponsors (+49%).

    Business unit performance

    Global Markets (GM) continued to deliver strong growth across all strategic areas, with currencies (FX) and equities playing a key role. Revenues reached €1,847 million through September, up 27% year-on-year. FX saw exceptional performance in Turkey and Mexico, driven by significantly higher trading volumes and the volatility stemming from geopolitical tensions. The equities business benefited from strong institutional activity in the U.S. and Asia, as well as the integration of BBVA Trader into the retail channels. The positive performance of the rates business was supported by activity in the U.S. and the financing business. Meanwhile, the credit business continued to perform solidly in the U.S., Europe and Mexico, underpinned by strong origination activity.

    Global Transaction Banking (GTB) maintained strong momentum in the third quarter of 2025, with cumulative revenues reaching €1,841 million in the first nine months of the year, a 19% increase versus the same period in 2024. This performance reflects the consolidation of structured receivables solutions and notable progress in inventory, liquidity and supply chain management. Sustained growth was recorded in key markets, supported by higher transaction volumes across geographies and business units within the Group. These factors contributed to year-on-year improvements despite a more challenging environment marked by lower returns on interest rates and persistent geopolitical tensions. In this context, activity reached record levels in loans, deposits and guarantees, driving double-digit growth in both net interest income and fees. As a result, GTB’s efficiency ratio remained below industry standards, reflecting highly effective execution.

    Investment Banking & Finance (IB&F) delivered an outstanding performance in the first nine months of the year, with results reaching €1,038 million, a 35% increase compared to the same period in 2024. This strong performance was mainly driven by corporate lending activity in the U.S., United Kingdom, Rest of Europe and Mexico, as well as structured trade finance in Spain and Rest of Europe. In addition, project finance continued to show strong momentum, particularly in the U.S. and Europe, with renewable energy and TMT projects as the main drivers of growth.

    In a context marked by geopolitical uncertainty and market volatility, corporate finance activity remained resilient and dynamic, posting a significant increase in revenues over the nine-month period.

    Cross-border business at BBVA CIB

    Cross-border business continues to be one of the key growth drivers for BBVA CIB, strengthening market connectivity and supporting clients in their international expansion. So far this year, it already accounts for 43% of the division’s total revenues, following a strong momentum in recent months that has resulted in 17% growth. Mexico remains the most attractive market for clients, while the franchise continues to deepen its presence in the United States and United Kingdom, and relevant transactions are being closed in Brazil. This progress is underpinned by large structured financing deals and the development of innovative global trade finance solutions, particularly in prepayments and inventory finance.

    Sustainability as a business driver

    Between January and September 2025, BBVA CIB channelled approximately €49,700 million in sustainable finance, a 36% year-on-year increase. BBVA continues to promote the financing of clean technologies (cleantech) and renewable energy projects in the wholesale segment, as well as solutions such as sustainability-linked supply chain finance (confirming). Notably, financing for renewable energy projects reached €2,100 million through September.

    Continue Reading

  • Using Artificial Intelligence To Track Proteins

    Using Artificial Intelligence To Track Proteins

    A database for AI-generated molecular “fingerprints”

    Since 2022, MSAID has been marketing a patented successor of the software whose prototype sparked the company’s founding. It streamlines the analysis of complex, large datasets. MSAID COO…

    Continue Reading

  • Hardy MP, Owczarek CM, Jermiin LS, Ejdebäck M, Hertzog PJ. Characterization of the type I interferon locus and identification of novel genes. Genomics. 2004;84:331–45.

    CAS 
    PubMed 

    Google Scholar 

Continue Reading

  • Sensors Information | AZoSensors.com – Page not found

    Sensors Information | AZoSensors.com – Page not found

    While we only use edited and approved content for Azthena
    answers, it may on occasions provide incorrect responses.
    Please confirm any data provided with the related suppliers or

    Continue Reading

  • Hyundai Motor Drives into the Virtual Drifting World with INSTEROID Electric Concept Car in JDM: Japanese Drift Master

    • Hyundai Motor Company introduces its electric concept vehicle, INSTEROID, in the drift racing game JDM: Japanese Drift Master
    • The launch at the Japan Mobility Show blends a physical concept car showcase with its in-game counterpart for a…

    Continue Reading

  • Association Between Non-HDL/HDL Cholesterol Ratio and Urinary Incontin

    Association Between Non-HDL/HDL Cholesterol Ratio and Urinary Incontin

    Introduction

    UI is a prevalent chronic health condition worldwide, with particularly high incidence rates among middle-aged and postmenopausal women, affecting approximately 44% to 57% of this population.1 Beyond its physical implications—such…

    Continue Reading

  • 5 Questions With Japanese Actress Kumi Takiuchi

    5 Questions With Japanese Actress Kumi Takiuchi

    With two acclaimed indie features screening back-to-back at last year’s Tokyo International Film Festival — Keiko Tsuruoka’s Ravens and Kiyoshi Sugiyama’s award winner Teki Cometh — actress Kumi Takiuchi cemented her standing as one…

    Continue Reading

  • Siemens and Capgemini deepen partnership to empower industries for the next era of manufacturing

    Siemens and Capgemini deepen partnership to empower industries for the next era of manufacturing





    Siemens and Capgemini deepen partnership to empower industries for the next era of manufacturing – Capgemini














    Siemens and Capgemini deepen partnership to empower industries for the next era of manufacturing – Capgemini













    Continue Reading

  • Review of the European Academy of Dermatology and Venereology (EADV) Congress 2025

    Review of the European Academy of Dermatology and Venereology (EADV) Congress 2025

    THIS AUTUMN, Paris, France, hosted the 34ᵗʰ annual European Academy of Dermatology and Venereology (EADV) Congress. For the second time in its history, the event took place in the French capital, attracting over 20,000 delegates. This…

    Continue Reading